Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1121896

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Allergies: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of the availability of adrenaline auto-injectors.
	tabling member constituency	Lewisham, Deptford
	tabling member printed	Vicky Foxcroft
	uin	245895
	answer	answer is ministerial correction date of answer 30/04/2019 answer text <p>Supplies of EpiPen and other adrenaline auto-injectors are currently available in volumes that are sufficient to meet normal levels of demand. The Department continues to work very closely with all the manufacturers of adrenaline auto-injectors and can confirm that the supply situation continues to improve with further deliveries expected over the coming months. All patients who require an adrenaline auto-injector should now be able to obtain a device from their pharmacy.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 245896 question first answered 30/04/2019 13:08:53 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4491 label Biography information for Vicky Foxcroft

1121898

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Allergies: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that users are protected in the event that they are unable to have their prescriptions for adrenaline auto-injectors fulfilled by pharmacists.
	tabling member constituency	Lewisham, Deptford
	tabling member printed	Vicky Foxcroft
	uin	245896
	answer	answer is ministerial correction date of answer 30/04/2019 answer text <p>Supplies of EpiPen and other adrenaline auto-injectors are currently available in volumes that are sufficient to meet normal levels of demand. The Department continues to work very closely with all the manufacturers of adrenaline auto-injectors and can confirm that the supply situation continues to improve with further deliveries expected over the coming months. All patients who require an adrenaline auto-injector should now be able to obtain a device from their pharmacy.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 245895 question first answered 30/04/2019 13:08:53 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4491 label Biography information for Vicky Foxcroft

1124298

	registered interest
	date	01/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Public Health: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the effect of changes in the level of public health budgets on patients’ health.
	tabling member constituency	Lewisham, Deptford
	tabling member printed	Vicky Foxcroft
	uin	250010
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>Local authorities will receive over £3.1 billion in 2019/20 for use on public health. It is for local authorities themselves to determine how best to use these resources based on their assessment of local need and with regard to their statutory duties. This funding is in addition to what the National Health Service spends on preventative interventions such as immunisation and screening, including over £1.2 billion on national public health functions in 2018/19.</p><p>Public Health England monitors and publishes data on trends for the wide range of indicators of public health set out in the Public Health Outcomes Framework. Most are stable or improving. The framework can be found at the following link:</p><p><a href="https://www.gov.uk/government/collections/public-health-outcomes-framework" target="_blank">https://www.gov.uk/government/collections/public-health-outcomes-framework</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 16:05:24 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4491 label Biography information for Vicky Foxcroft

1131666

	registered interest
	date	12/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Arthritis: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of training for GPs in the early diagnosis of rheumatoid arthritis.
	tabling member constituency	Rochdale
	tabling member printed	Tony Lloyd
	uin	263716
	answer	answer is ministerial correction date of answer 17/06/2019 answer text <p>General practice is where most patients with musculoskeletal conditions, including rheumatoid arthritis (RA) are likely to be managed, and the condition is identified as a key area of clinical knowledge in the Royal College of General Practitioners’ Advanced Knowledge Test (AKT) content guide. The AKT is a summative assessment of the knowledge base that underpins general practice in the United Kingdom within the context of the National Health Service and is a key part of general practitioner’s qualifying exams.</p><p>No specific assessment has been made on the adequacy of access to specialist rheumatologists, however the National institute for Health and Care Excellence’s (NICE) Quality Standard ‘Rheumatoid arthritis in over 16s’, updated in July 2018, emphasises the need for early for urgent referral to a specialist rheumatologist on suspicion of rheumatoid arthritis within three weeks.</p><p>In May 2018, a new three-year Rheumatoid and Early Inflammatory Arthritis Audit was commissioned by the Healthcare Quality Improvement Partnership. The Audit aims to improve the quality of care for people living with inflammatory arthritis, collecting information on all new patients over the age of 16 in specialist rheumatology departments with suspected inflammatory arthritis in England and Wales using criteria derived from sources, including the NICE rheumatoid arthritis Quality Standard. This includes assessment against the NICE standard stating that patients with suspected with RA should be seen within three weeks of referral to a rheumatology service.</p><p>More information can be found at the following link:</p><p><a href="http://www.rheumatology.org.uk/Knowledge/Excellence/Audits" target="_blank">www.rheumatology.org.uk/Knowledge/Excellence/Audits</a></p><p>The findings of the Audit are due to be published in October 2019. However, previous Audit reports can be found at the following link:</p><p><a href="http://www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory" target="_blank">www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory</a></p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263717 question first answered 17/06/2019 14:54:50 answering member 4455 label Biography information for Seema Kennedy
	tabling member	450 label Biography information for Tony Lloyd

1131669

	registered interest
	date	12/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rheumatology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of access to specialist rheumatologists.
	tabling member constituency	Rochdale
	tabling member printed	Tony Lloyd
	uin	263717
	answer	answer is ministerial correction date of answer 17/06/2019 answer text <p>General practice is where most patients with musculoskeletal conditions, including rheumatoid arthritis (RA) are likely to be managed, and the condition is identified as a key area of clinical knowledge in the Royal College of General Practitioners’ Advanced Knowledge Test (AKT) content guide. The AKT is a summative assessment of the knowledge base that underpins general practice in the United Kingdom within the context of the National Health Service and is a key part of general practitioner’s qualifying exams.</p><p>No specific assessment has been made on the adequacy of access to specialist rheumatologists, however the National institute for Health and Care Excellence’s (NICE) Quality Standard ‘Rheumatoid arthritis in over 16s’, updated in July 2018, emphasises the need for early for urgent referral to a specialist rheumatologist on suspicion of rheumatoid arthritis within three weeks.</p><p>In May 2018, a new three-year Rheumatoid and Early Inflammatory Arthritis Audit was commissioned by the Healthcare Quality Improvement Partnership. The Audit aims to improve the quality of care for people living with inflammatory arthritis, collecting information on all new patients over the age of 16 in specialist rheumatology departments with suspected inflammatory arthritis in England and Wales using criteria derived from sources, including the NICE rheumatoid arthritis Quality Standard. This includes assessment against the NICE standard stating that patients with suspected with RA should be seen within three weeks of referral to a rheumatology service.</p><p>More information can be found at the following link:</p><p><a href="http://www.rheumatology.org.uk/Knowledge/Excellence/Audits" target="_blank">www.rheumatology.org.uk/Knowledge/Excellence/Audits</a></p><p>The findings of the Audit are due to be published in October 2019. However, previous Audit reports can be found at the following link:</p><p><a href="http://www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory" target="_blank">www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory</a></p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263716 question first answered 17/06/2019 14:54:50 answering member 4455 label Biography information for Seema Kennedy
	tabling member	450 label Biography information for Tony Lloyd

1133166

	registered interest
	date	19/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	266861
	answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:42:09 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4623 label Biography information for Tonia Antoniazzi

1133167

	registered interest
	date	19/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	266862
	answer	answer is ministerial correction date of answer 27/06/2019 answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 27/06/2019 12:43:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4623 label Biography information for Tonia Antoniazzi

1110582

	registered interest
	date	09/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Silica: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect on human health of exposure to silica dust; what (a) guidance and (b) legislative measures are in place to control human exposure to silica dust; and if he will make a statement.
	tabling member constituency	West Bromwich East
	tabling member printed	Tom Watson
	uin	242745
	answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>Many studies have indicated that silica dust can be harmful when inhaled. In the United Kingdom, all workplaces must comply with the Control of Substances Hazardous to Health Regulations 2002, which sets a workplace exposure limit for silica. Occupational health and safety is under the remit of the Health and Safety Executive, who have issued guidance and advice to help employers manage risks and to raise awareness of the importance of controlling exposure to harmful materials at work which is available at the following link:</p><p> </p><p><a href="http://www.hse.gov.uk/pubns/indg463.pdf" target="_blank">http://www.hse.gov.uk/pubns/indg463.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/04/2019 13:02:57 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1463 label Biography information for Lord Watson of Wyre Forest

1139200

	registered interest
	date	16/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sugar: Advertising
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential benefits to public health of stopping the advertising of high sugar milk and milk-replacement products on public transport.
	tabling member constituency	West Bromwich East
	tabling member printed	Tom Watson
	uin	277679
	answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>The Department has not assessed the potential benefits to public health of stopping the advertising of high sugar milk and milk-replacement products on public transport.</p><p> </p><p>As committed to in the second chapter of our childhood obesity plan, published in June 2018, the Department of Health and Social Care and the Department for Digital, Culture, Media and Sport have jointly consulted on introducing further advertising restrictions for products high in fat, sugar and salt (HFSS) on TV and online. As part of this consultation we invited views on whether the scope of this consultation should be extended to other forms of media and how HFSS products should be defined. We have received a high level of responses to the consultation and it is important we take the time to consider them carefully before we set out further action.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 15:44:18 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1463 label Biography information for Lord Watson of Wyre Forest

1138460

	registered interest
	date	11/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Smoking
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of Clinical Commissioning Groups do not allow varenicline and other stop smoking treatments to be prescribed to patients in primary care; and if he will make a statement.
	tabling member constituency	Corby
	tabling member printed	Tom Pursglove
	uin	276206
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>NHS England has advised that, because this is a locally commissioned service, they do not hold this information centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/07/2019 09:24:56 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4369 label Biography information for Tom Pursglove